Akums Drugs Q1 Profit Jumps 57.5% to Rs 100 Cr; Stock Surges
By Business Desk
Akums Drugs & Pharmaceuticals reports a 57.5% year-on-year Q1 net profit increase to Rs 100 crore, driving its stock up over 5%. Revenue and EBITDA also saw significant growth.
Akums Drugs and Pharmaceuticals recorded a significant intraday stock surge of more than 5% today, driven by its robust financial performance in the first quarter.
The pharmaceutical company announced its consolidated net profit increased by 57.5% year-on-year, reaching Rs 100 crore. This profit growth substantially outpaced the 13.9% rise in revenue from operations, which stood at Rs 1,167 crore for the quarter.
Key Q1 Financials
- Consolidated Net Profit: Up 57.5% YoY to Rs 100 crore.
- Revenue from Operations: Increased 13.9% to Rs 1,167 crore.
- Consolidated EBITDA: Rose 35.5% to Rs 175 crore.
- EBITDA Margin: Expanded to 15% from 12.6% year-on-year.
The company’s operational efficiency notably improved, as evidenced by its consolidated EBITDA margin expanding from 12.6% in the previous year to 15%. This margin growth underscores effective cost management and stronger profitability.
Stock Performance Overview
- Intraday Gain: More than 5%.
- Six-Month Return: Delivered 57%.
- 2026 Rally: Achieved 64%.
- Current Trading Price: Rs 732 apiece on the NSE.
Akums Drugs and Pharmaceuticals shares are currently trading at Rs 732 apiece on the NSE. The strong quarterly results have fueled investor confidence, with the stock delivering a 57% return over the past six months and a 64% rally in 2026.